

1 **A step forward, but still inadequate: Australian health professionals' views on the genetics and life**  
2 **insurance moratorium**

3  
4 **Authors:**

5 # Jane Tiller<sup>1, 2</sup>, (<https://orcid.org/0000-0003-3906-6632>)  
6 Louise Keogh<sup>3</sup>  
7 Aideen McInerney-Leo<sup>4</sup>  
8 Andrea Belcher<sup>5,6</sup> (<https://orcid.org/0000-0002-3331-5637>)  
9 Kristine Barlow-Stewart<sup>7</sup>  
10 Tiffany Boughtwood<sup>2,6</sup> (<https://orcid.org/0000-0002-9634-3731>)  
11 Penny Gleeson<sup>8</sup> (<https://orcid.org/0000-0003-2798-1649>)  
12 Grace Dowling<sup>1</sup>  
13 Anya E.R. Prince<sup>9</sup> (<https://orcid.org/0000-0002-0086-7881>)  
14 Yvonne Bombard<sup>10</sup>  
15 Yann Joly<sup>11</sup>  
16 Martin B Delatycki<sup>2, 12</sup>  
17 Ingrid Winship<sup>13, 14</sup>  
18 Margaret Otlowski<sup>15</sup> ([Orcid.org/0000-0003-4707-4325](https://orcid.org/0000-0003-4707-4325))  
19 Paul Lacaze<sup>1</sup> ([orchid: 0000-0002-0902-6798](https://orcid.org/0000-0002-0902-6798))  
20

21 **Affiliations**

22 <sup>1</sup> Public Health Genomics, School of Public Health and Preventive Medicine, Monash University,  
23 Melbourne, Australia  
24 <sup>2</sup> Murdoch Children's Research Institute, Parkville, Australia  
25 <sup>3</sup> Centre for Health Equity, Melbourne School of Population and Global Health, The University of  
26 Melbourne, Melbourne, Australia  
27 <sup>4</sup> The University of Queensland Diamantina Institute, University of Queensland, Dermatology  
28 Research Centre, Brisbane, Australia  
29 <sup>5</sup> Faculty of Medicine, University of Queensland, Brisbane, Australia  
30 <sup>6</sup> Australian Genomics, Melbourne, Australia  
31 <sup>7</sup> Sydney Medical School, University of Sydney, Sydney, Australia  
32 <sup>8</sup> Deakin Law School, Melbourne, Australia  
33 <sup>9</sup> University of Iowa College of Law, Iowa City, United States  
34 <sup>10</sup> University of Toronto, Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, Canada.  
35 <sup>11</sup> The Genetic Discrimination Observatory, Department of Human Genetics, McGill University,  
36 Montreal, Canada  
37 <sup>12</sup> Victorian Clinical Genetics Services, Parkville, Australia  
38 <sup>13</sup> Department of Medicine, the University of Melbourne, Melbourne, Australia.  
39 <sup>14</sup> Genomic Medicine and Family Cancer Clinic, Royal Melbourne Hospital, Parkville, Australia  
40 <sup>15</sup> Faculty of Law and Centre for Law and Genetics, University of Tasmania, Hobart, Australia  
41

42 # corresponding author

43 Jane Tiller, LLB, MGenCouns  
44 Monash University, School of Public Health and Preventive Medicine  
45 Level 5, 99 Commercial Road, 3004 Melbourne, VIC, Australia  
46 email: [jane.tiller@monash.edu](mailto:jane.tiller@monash.edu)

47 **ABSTRACT**

48 **Background**

49 In 2019, the Australian life insurance industry introduced a partial moratorium (ban) limiting the use  
50 of genetic test results in life insurance underwriting. The moratorium is industry self-regulated and  
51 applies only to policies below certain financial limits (eg AUD\$500,000 of life cover).

52 **Methods**

53 We surveyed Australian health professionals (HPs) who discuss genetic testing with patients, to assess  
54 knowledge of the moratorium; reported patient experiences since its commencement; and HP views  
55 regarding regulation of genetic discrimination (GD) in Australia.

56 **Results**

57 Between April-June 2020, 166 eligible HPs responded to the online survey. Of these, 86% were aware  
58 of the moratorium, but <50% had attended related training/information sessions. Only 16% answered  
59 all knowledge questions correctly, yet 69% believed they had sufficient knowledge to advise patients.  
60 Genetics HPs' awareness and knowledge were better than non-genetics HPs' ( $p < 0.05$ ). There was  
61 some reported decrease in patients delaying/declining testing after the moratorium's introduction,  
62 however 42% of HPs disagreed that patients were more willing to have testing post-moratorium.  
63 Although many (76%) felt the moratorium resolved some GD concerns, most (88%) still have concerns,  
64 primarily around self-regulation, financial limits and the moratorium's temporary nature. Almost half  
65 (49%) of HPs reported being dissatisfied with the moratorium as a solution to GD. The majority (95%)  
66 felt government oversight is required, and 93% felt specific Australian legislation regarding GD is  
67 required.

68 **Conclusion**

69 While the current Australian moratorium is considered a step forward, most HPs believe it falls short  
70 of an adequate long-term regulatory solution to GD in life insurance.

71 **Key words:** genetic discrimination; life insurance; moratorium; ethics; health professional

72 **Introduction**

73 Genetic discrimination (GD) is an area of international concern[1-4]. In the context of life insurance,  
74 GD can lead to increased premiums or denial of insurance applications. Predictive genetic testing  
75 (where an individual has not developed disease but genetic testing can reveal a higher risk of  
76 developing disease) can save lives due to preventative interventions or early treatment of disease. In  
77 Australia and internationally, research shows that fear of insurance implications deters some at-risk  
78 individuals from having clinically-indicated predictive genetic testing or participating in research[5-  
79 10].

80

81 In Australia, the issue of GD in health insurance does not arise, because health insurance premiums  
82 are community-rated rather than personally risk-rated under the *Private Health Insurance Act 2007*  
83 (Cth). However, life insurance companies can legally ask for and use applicant's genetic test results to  
84 make underwriting decisions, under a specific exemption in s46 of the *Disability Discrimination Act*  
85 1992 (Cth) (DDA). Despite consideration of the potential for GD arising from this exemption in 2001-  
86 03[11], the Australian government continues to allow the life insurance industry to self-regulate their  
87 access to and use of applicants' genetic information. The inherently conflicted model of industry self-  
88 regulation for life insurance raises numerous ethical and societal concerns[12]. These have been  
89 reflected in government inquiries into the insurance and financial services industries in recent  
90 years[13 14].

91

92 In 2018, the Australian Parliamentary Joint Committee on Corporations and Financial Services released  
93 recommendations arising out of its inquiry into the life insurance industry[14]. These included  
94 recommending a ban (moratorium) on life insurers' use of predictive genetic test results for  
95 underwriting, as well as recommending government monitoring and introduction of legislation if  
96 necessary. The Australian government has not yet responded to these recommendations. However,  
97 in 2019, the Financial Services Council (FSC), the peak industry body for Australian life insurers,

98 voluntarily introduced an industry self-regulated moratorium on the use of genetic test results by their  
99 member organisations[15 16]. The FSC moratorium, which applies only to FSC member companies,  
100 restricts insurers' access to and use of genetic test results for applications for life insurance cover for  
101 or below AUD\$500,000 only. Because travel insurance falls within general insurance, as distinct from  
102 life insurance, it is not restricted by the moratorium and genetic test results can legally be used to  
103 discriminate in underwriting, pursuant to s46 of the DDA.

104

105 As a self-regulated industry standard, the FSC moratorium is not legally binding or enforceable; nor is  
106 it subject to government regulation or oversight. Legally, the insurance industry's right to use genetic  
107 test results in underwriting in accordance with the DDA remains and is not affected by the  
108 implementation of the FSC moratorium, which will be reviewed in 2022 and end in 2024, if not  
109 renewed. The FSC have a Code of Practice, compliance with which is monitored by an external  
110 committee of three persons including a consumer representative, an industry representative and an  
111 independent chair[17]. At the time of publication, the FSC moratorium has not been incorporated into  
112 the Code of Practice, although we understand that this is FSC's intention in future.

113

114 Health professionals (HPs) are key to ensuring that patients who are considering genetic testing are  
115 adequately advised of the potential for life insurance discrimination before testing is undertaken.  
116 Further, they often witness the deterrent effects of fears about life insurance implications, or hear  
117 firsthand of GD experiences[18]. Australian professional guidelines state that a discussion of insurance  
118 implications should be part of each genetic counselling session where relevant[19]. With the  
119 progressive mainstreaming of genetic testing in Australia, a greater proportion of clinicians without  
120 genetics training are discussing genetic testing with patients[20]. A recent systematic review[21]  
121 found non-genetics HPs (nurses and physicians) had limited genetics knowledge and were unprepared  
122 for integrating genomics into clinical care. However, little is known about non-genetics HPs'  
123 knowledge regarding life insurance discrimination, the moratorium, and the implications for patients.

124

125 Prior to the introduction of the FSC moratorium, we surveyed genetics professionals in Australia about  
126 their patients' experiences regarding life insurance discrimination and their views on regulation of this  
127 area [18]. That study demonstrated some deficits both in knowledge regarding use of genetic testing  
128 in insurance underwriting, and self-reported confidence in advising patients about insurance  
129 implications. It also captured widespread concerns regarding regulation in the area of GD, with the  
130 vast majority of HPs reporting a view that current Australian regulations were inadequate to protect  
131 patients from GD.

132

133 To our knowledge, there has been no survey of HPs following the introduction of the FSC moratorium.  
134 This study forms a key part of the Australian Genetics and Life Insurance Moratorium: Monitoring the  
135 Effectiveness and Response (A-GLIMMER) Project - funded by the Australian government[22 23]. The  
136 purpose of the Project is to assess the extent to which the FSC moratorium achieves the policy aims  
137 identified by the Parliamentary Joint Committee on Corporations and Financial Services. This  
138 particular study contributes to that Project by analysing the effectiveness of the FSC moratorium in  
139 relation to HPs. The aim of this study is to describe the knowledge, experiences and perspectives of  
140 HPs that discuss genetic testing with patients, following the commencement of the FSC moratorium.  
141 Where possible, it will also compare those findings with findings from the pre-moratorium research  
142 study[18].

143

## 144 **Methods**

### 145 Population, sampling and recruitment

146 The protocol paper for the A-GLIMMER project has been published previously[23]. The population of  
147 interest was qualified health professionals working in a health service in Australia, who regularly  
148 discuss genetic testing with patients. Eligibility was established through screening questions at the

149 beginning of the questionnaire. A range of targeted recruitment strategies were adopted to capture a  
150 broad sample:

- 151 • Newsletters emailed directly to members of the Human Genetics Society of Australasia  
152 (HGSA), Australasian Society of Genetic Counsellors, Royal Australasian College of Physicians,  
153 and the Australian Genomics Health Alliance
- 154 • Social media advertisements (Twitter and Facebook)
- 155 • Direct email to colleagues and personal contacts of the authors
- 156 • Snowball sampling (requesting HPs and personal contacts forward an email invitation to their  
157 professional networks)

#### 158 Survey development and data collection

159 We used an online survey conducted using REDCap software[24] (see Supplementary Materials for a  
160 copy of the survey). The survey was adapted from our previous survey of HPs administered prior to  
161 the commencement of the FSC moratorium[18]. Relevant questions were preserved for comparison,  
162 and new questions were introduced to determine the impact and effectiveness of the moratorium in  
163 relation to HPs' knowledge, experience and views. The adapted survey included sections relating to  
164 demographics; awareness, training, and knowledge; patient attitudes, behaviours, and reported  
165 experiences; and personal views regarding regulation of GD. Validated scales were unavailable for  
166 questions specific to the moratorium, however the survey was developed in consultation with a  
167 number of clinical and research partners, and was pre-tested with a clinical geneticist, a genetic  
168 counsellor and a lay person without health qualifications. Data were mostly collected through closed-  
169 ended responses using Likert scales and fixed alternative options, with a small number of open-ended  
170 questions where free text was allowed. The survey was open for response from April–June 2020,

171

#### 172 Data analysis

173 Descriptive analysis was conducted for closed-ended questions. Descriptive statistics were reported  
174 for each question included in the results, broken down by total number of HPs, as well as separately

175 by genetics HPs and non-genetics HPs. Six questions evaluated knowledge (true/false/unsure) about  
176 aspects of the FSC moratorium and current insurance implications). HPs received a point for every  
177 correct answer (range 0–6). A mean knowledge score was calculated for comparison between groups.  
178 The percentage of correct answers for each item was also calculated. Knowledge scores were  
179 categorised into “good knowledge” (5-6 questions answered correctly), “average knowledge” (3-4  
180 correct), and “poor knowledge” (0-2 correct). Z-tests were used to test for significance of differences  
181 between groups, with p-values (2-sided) <0.05 considered significant. STATA 14 was used for  
182 analysis[25].

183

184 Responses to open-ended questions were reviewed and sorted into common categories, which were  
185 reported in detail in the supplementary materials and in summary form with example quotes in the  
186 manuscript.

187

## 188 **Results**

189 Overall, 166 eligible HPs participated in the online survey. As some HPs discontinued the survey before  
190 reaching the end, the number of HPs who answered each individual question varied (range n=144-  
191 166). To aid readability, the “n” for every reported figure is not given in the text, but is included at  
192 each instance in the accompanying figures and tables. Given the diverse recruitment strategies, it is  
193 difficult to estimate a total response rate relative to all eligible participants. However, at the time of  
194 recruitment, the HGSA distribution list included 484 clinical geneticists (CGs) and genetic counsellors  
195 (GCs). Of the 166 HPs who participated, 111 were CGs or GCs, making the response rate for those  
196 categories in the profession field an estimated 23%.

197

198 Table 1 shows the characteristics of the surveyed population. The “Other” category under the  
199 profession field is comprised of HPs representing more than 15 different fields, all of whom were  
200 eligible for the study as they reported regularly discussing genetic testing with patients. These

201 included surgery, nursing, psychiatry, metabolics, cardiology, pathology, neurology, endocrinology,  
202 gastroenterology, haematology, immunology, obstetrics, paediatrics, and others (see Supplementary  
203 Table S1). These HPs are referred to as “non-genetics HPs”, as distinguished from “genetics HPs”  
204 (genetic counsellors, clinical geneticists, and genetics fellows).

205

#### 206 Awareness, knowledge and training (Table 2 and Figure 1)

207 Most HPs (86%) overall, but just over half (53%) of non-genetics HPs were aware of the FSC  
208 moratorium. Over half of genetics HPs (55%) reported attending training or information sessions  
209 regarding the moratorium and insurance implications of genetic testing training, while few non-  
210 genetics HPs had done so (7%). There are two well-known fact sheets on the moratorium: the Centre  
211 for Genetics Education (CGE) Fact Sheet 20[26], and the FSC insurance and genetics moratorium fact  
212 sheet[27]. A majority of HPs (65%) had read at least one of these fact sheets. However, only a third  
213 (n=14) of non-genetics HPs had read a fact-sheet, compared to 76% (n=89) of genetics HPs (z=5;  
214 p<0.05).

215

216 Many HPs (69%) felt that they had sufficient knowledge about current insurance implications to  
217 properly advise clients. On the objective knowledge test, about half (49%) had good knowledge (5-6  
218 questions answered correctly) (see Table S2 for question-specific data). More genetics HPs answered  
219 questions correctly (mean 4.5/6) than non-genetics HPs (mean 3.1/6) (z=7.3; P<0.05). Of the 50  
220 genetics HPs who answered two or more questions incorrectly (average/poor knowledge), about  
221 three-quarters (n=38) felt they understood insurance implications for individuals undergoing genetic  
222 testing extremely/reasonably well, and almost two-thirds (n=30) felt they had sufficient knowledge to  
223 properly advise patients. However, of 25 non-genetics HPs who answered two/more incorrectly, only  
224 a quarter felt they understood insurance implications extremely/reasonably well, (n=6) and a fifth  
225 (n=5) felt they had sufficient knowledge. These differences between genetics and non-genetics HPs  
226 were significant (z=4.3 (understanding) z=3.3 (knowledge), p<0.05).



227

228 *Impact on practice and testing (Table 3)*

229 HPs were asked in this survey about how often patients either delayed or declined having predictive  
230 genetic testing due to life insurance concerns, both before the moratorium was introduced and then  
231 after the moratorium was introduced (Fig 2A and 2B). Overall, 63% of HPs said patients delayed testing  
232 because of life insurance concerns often/sometimes before the moratorium, and 39% said they  
233 delayed often/sometimes after the moratorium was introduced ( $z=4.15$ ;  $p<0.05$ ). Similarly, 39% said  
234 patients refused testing due to life insurance concerns often/sometimes pre-moratorium, compared  
235 with 18% post-moratorium ( $z=4.18$ ;  $p<0.05$ ).

236

237 Although the FSC moratorium does not apply to travel insurance, this can be a source of some  
238 confusion for both patients and consumers. GD in travel insurance was raised as an issue by several  
239 HPs in free-text responses (see below). When asked about how often patients delay or decline  
240 predictive testing due to travel insurance concerns, 11% of HPs said patients delay often/sometimes,  
241 and 12% said patients refuse often/sometimes.

242

243 *Views on the FSC moratorium's effectiveness and regulation (Table 4)*

244 Almost all HPs (93%) agreed/strongly agreed that “consumers are better protected post-moratorium  
245 than they were before the moratorium was introduced”. Although 76% felt the FSC moratorium  
246 resolved some concerns the HPs had about insurance discrimination, 88% still had concerns about  
247 insurance discrimination after its introduction.

248

249 Most HPs agreed/strongly agreed that the FSC moratorium is easy to understand (80%) and easy to  
250 explain to patients (76%); however, a number (20% and 24% respectively), disagreed/strongly  
251 disagreed, showing a portion of HPs find it difficult to understand and/or explain. HPs were split  
252 almost evenly in their views regarding both questions “patients are less confused than they used to be

253 *about insurance implications of genetic testing*" (51% agreed/strongly agreed; 49% disagreed/strongly  
254 disagreed) and *"patients are more willing to have predictive genetic testing than they were before the*  
255 *moratorium was introduced"* (59% agreed/strongly agreed; 41% disagreed/strongly disagreed).

256

257 The vast majority (95%) of HPs (with no significant difference between genetics and non-genetics HPs  
258 ( $z=0.2$ ;  $p=0.83$ )) stated that a formal agreement between government and the life insurance industry  
259 (as exists in the UK) is required in Australia (Fig 2C). This question allowed optional free text to allow  
260 for HPs to elaborate on their answer (see Table S3 for all free-text responses grouped into categories).  
261 Of 149 HPs, 22 elected to elaborate (21 who said yes, 1 who said no). Of those who said yes, one-third  
262 expressed concerns with industry self-regulation. For example, Participant 129 (genetic counsellor, 0-  
263 5 years' experience) stated, *"I think that the industry needs to be held accountable; I don't trust that*  
264 *the self-governing model is enough."*

265

266 Two HPs felt that further regulation may be needed, but the decision should depend on the outcomes  
267 of the FSC moratorium, with Participant 127 (genetic pathologist, 15-20 years' experience) stating,  
268 *"We need an evidence-based approach. We should wait for results to emerge from the current*  
269 *moratorium."* The HP who said no and chose to elaborate (Participant 109, clinical geneticist, 15-20  
270 years' experience) stated, *"Insurance companies currently load premiums or withhold cover on much*  
271 *less scientific premises than genetic test results. By making these 'special' we do more harm than good*  
272 *by making people afraid of genetic testing and complicating the process"*.

273

274 The vast majority (93%) of HPs also indicated that the Australian government should introduce  
275 legislation to regulate the use of genetic test results in life insurance (no significant difference between  
276 genetics/non-genetics HPs ( $z=-0.1$ ;  $p=0.94$ )) (Fig 2D). Of 149 HPs, 15 elaborated (13 "yes"; 3 "no")  
277 (Table S3). Four HPs expressed mistrust of insurers, with Participant 207 (genetic counsellor, >20  
278 years' experience) stating, *"if it is not in law, why would an insurance company do it?"*. Four HPs

279 commented that legally-enforceable/legislation-based regulation is required to ensure consumer  
280 protection; for example, Participant 135 (clinical geneticist, >20 years' experience) noted, *"this is the*  
281 *only way to protect people properly and not have the highly undesirable situation where people don't*  
282 *have genetic testing because of insurance concerns and die of preventable disease."*

283  
284 One HP's reason (Participant 256, Registered Nurse, >20 years' experience) for answering "no" to the  
285 government regulating insurer use of genetic information through legislation, appeared to be that  
286 insurer use should not be allowed *at all*, stating, *"Sorry, too many instances where insurance*  
287 *companies look to preserving their cash and not interested in helping people with genuine need."*

288 Participant 229 (clinical geneticist, 15-20 years' experience) answered no *"with the caveat that self-*  
289 *regulation is effective and sufficient monitoring is in place"* along with 2 others who stated that any  
290 regulation should be evidence-based. The other "no" HP (Participant 109, clinical geneticist, 15-20  
291 years' experience) explained that, *"People accept that information available will be used by insurance*  
292 *companies. They don't generally have a problem with this"*.

293  
294 When asked about how insurers' compliance with the FSC moratorium on using genetic test results in  
295 life insurance should be regulated, 88% of HPs chose "regulation through legally enforceable rules".  
296 Thirteen percent (n=20) chose self-regulation by the FSC, though 7 of these also chose "legally  
297 enforceable rules" indicating a preference for a blended regulatory approach. Forty-nine percent of  
298 HPs felt either very or somewhat dissatisfied with the moratorium as a solution to GD in life insurance.  
299 Only 4% felt "very satisfied".

300

### 301 *Benefits and limitations of the moratorium (Table 5)*

302 Sixty-two HPs responded to the optional free-text question "In your opinion, what, if any, are/have  
303 been the benefits of the moratorium?" Table 5a sets out the categories of benefits that were  
304 expressed, with example quotes (see Supplementary Table S4 for full responses). The most common

305 responses were “increased reassurance/patients more willing to have genetic testing” (34%) and  
306 “some protection provided” (31%). Sixty-one HPs provided optional feedback to the question, “in your  
307 opinion, what, if any, are the limitations of the moratorium?” (Table 5b, Table S4). The most commonly  
308 raised limitations were “insurance companies' compliance/ self-regulation” (46%), “financial limits”  
309 (44%), and “temporary nature of the moratorium” (31%). Similar issues arose in free-text comments  
310 in the final question, “Do you have any final comments?” (Table S5). Of 21 HPs who responded with  
311 substantive comments about the FSC moratorium, a third (n=7) raised issues around the need for  
312 legislation/enforceability; 2 each expressed concerns with the temporary nature and the unjustness  
313 of discrimination based on uncontrollable factors; 1 reiterated the inadequacy of the financial limits;  
314 5 reported difficulty with understanding/explaining the moratorium to patients; and 3 expressed  
315 concerns with the applicability to travel insurance. No HPs made any positive comments about the  
316 moratorium in the final thoughts section.

317

318

319 **Discussion**

320 In this study, we surveyed Australian health professionals' (HPs) knowledge, experiences, and opinions  
321 regarding the current industry self-regulated moratorium on genetic testing and life insurance. We  
322 found that most HPs who discuss genetic testing with clients are aware of the FSC moratorium, though  
323 knowledge of key aspects of the moratorium could be improved. Both awareness of and knowledge  
324 about the moratorium are superior for genetics HPs than non-genetics HPs. Many HPs expressed a  
325 view that the moratorium had resolved some of their concerns with GD. However, the majority of HPs  
326 still have concerns regarding the potential for GD in life insurance and feel that the moratorium does  
327 not adequately address those concerns. Most HPs feel that the moratorium does not represent an  
328 adequate long-term regulatory solution for Australia. Specifically, the majority of HPs feel that more  
329 stringent consumer protections are required, especially in the form of stronger government regulation  
330 or legislation. Key findings of our study are summarized in Figure 3.

331

332 In our previous survey of Australian genetics HPs, conducted before the FSC moratorium was  
333 introduced[18], we found that only 9% (n=6/69) of HPs felt regulation at the time was adequate.  
334 Now, after the introduction of the FSC moratorium, we still find that >90% believe government  
335 regulation and legislation are required. Although the moratorium is seen as a step forward, most  
336 Australian HPs remain concerned about the potential for GD, and its impact on patients. We found  
337 evidence of recognition from HPs regarding improved consumer protections, compared with the pre-  
338 moratorium situation, with most HPs agreeing that consumers are better protected now, after the  
339 introduction of the FSC moratorium. When asked about benefits of the moratorium, some HPs cited  
340 increased willingness of patients to have genetic testing. However, despite some reported reduction  
341 in patients delaying or refusing testing for insurance reasons, more than 40% of HPs still disagreed  
342 that patients are more willing to have testing following the introduction of the FSC moratorium,  
343 suggesting the desired impact of the moratorium has not been fully achieved.

344

345 Although about half of HPs surveyed expressed some satisfaction with the FSC moratorium as a  
346 solution to GD in life insurance, about half were either somewhat or very dissatisfied with it, and a  
347 vast majority still had concerns about insurance discrimination post-moratorium. Primary concerns,  
348 expressed in free-text comments, centred around the nature of industry self-regulation, lack of  
349 government oversight, the financial limits on the moratorium and its temporary nature. Comments  
350 provided by HPs showed negative opinions - including distrust of insurers, the conflicted nature of  
351 industry self-regulation, the need for more stringent government regulation, the inadequacy of the  
352 current financial limits, and the temporary nature of the FSC moratorium (and the uncertainty this  
353 creates for patients in the future). A small minority of HPs felt that government regulation was not  
354 required, as either the moratorium was adequate or the government should wait and see whether it  
355 is effective before introducing further regulation.

356

357 Many countries have banned or restricted life insurers' access to genetic test results for underwriting  
358 purposes[28-30]. For example, Canada has implemented the *Genetic Nondiscrimination Act* (2017)  
359 (GNDA), which prevents insurers from using genetic test results, and the US' *Genetic Information*  
360 *Nondiscrimination Act* (2008) (GINA) bans the use of genetic test results in health insurance and  
361 employment contexts. The UK's moratorium (known since 2018 as the Code on Genetic Testing and  
362 Insurance[31]) was established in 2001 as an agreement between the insurance industry and the UK  
363 Government, to protect consumers in relation to the use of predictive genetic test results. A single  
364 exception applies to predictive genetic tests for Huntington's disease where the life insurance policy  
365 coverage is above £500,000 (~AUD\$910,000).

366

367 Almost all HPs surveyed believe that a formal agreement between government and industry is  
368 required for Australia. Further, most HPs felt that any moratorium should be regulated through legally  
369 enforceable rules from the Australian government, including specific legislation to regulate life  
370 insurers' use of genetic test results. Our findings demonstrate that HPs who offer genetic testing to

371 patients believe that the current policy situation is still inadequate and lacks sufficient consumer  
372 protections. Given that in our previous study 62% of HPs considered Australia should introduce such  
373 legislation, and 93% of current HPs considered that legislation was needed, it appears that the current  
374 FSC moratorium has not altered that perception for the majority of HPs.

375  
376 Although the FSC moratorium may soon be included in the FSC Code of Practice[17], compliance with  
377 this Code is monitored by a committee of three individuals and is not subject to any legal or regulatory  
378 oversight from government. There are no pathways for enforcement by consumers (other than  
379 complaints to the Financial Ombudsman Service), and the sanctions which can be imposed lack any  
380 legal weight or punitive power. Thus, inclusion of the moratorium in the Code in future may not  
381 alleviate HPs concerns regarding lack of government oversight of this issue.

382  
383 The demographics of HPs in this study are similar to those of our previous study[18]. However, the  
384 current cohort is larger (n=166, compared with n=87 previously) and more diverse due to the  
385 expanded recruitment strategy. This survey has highlighted the diversity of health professionals who  
386 are discussing genetic testing with patients, in line with the mainstreaming of genetic testing noted  
387 earlier. This has also captured, for the first time in Australia, the perceptions of these HPs on this issue.

388  
389 Although there was consensus among most HPs from genetics and non-genetics backgrounds on key  
390 issues, including regulation, there was also divergence between genetics and non-genetic HPs in some  
391 areas. Areas of divergence include awareness of the FSC moratorium, with only about half of non-  
392 genetics HPs who discuss genetic testing with patients being aware of the moratorium. Our results in  
393 this regard are consistent with other studies that report poor awareness or understanding of local  
394 non-discrimination laws/policies by HPs [32-34]. However, given the importance of considering  
395 insurance issues where relevant before deciding whether to have a genetic test, this lack of awareness  
396 is somewhat concerning, and raises questions about dissemination and how to more effectively raise

397 awareness, particularly among non-genetics HPs. The numbers of genetics and genetics HPs who had  
398 read either the CGE or FSC fact sheets indicate that these are a reasonable method of disseminating  
399 information to genetics HPs but not so effective for non-genetics HPs.

400

401 Another area of distinction between genetics and non-genetics HPs was in objective knowledge. When  
402 only considering genetic HPs, 81% felt they had sufficient knowledge of insurance implications to  
403 properly advise patients, which has increased from our previous research (61%; n=53/87)[18].  
404 However, only a small fraction of both genetics and non-genetics HPs answered all 6 questions about  
405 key aspects of the FSC moratorium correctly, and about half had average or poor knowledge. For non-  
406 genetics HPs, there was a reasonable match between subjective and objective lack of knowledge. This  
407 is consistent with international studies of non-genetics HPs, which found a correlation between HPs'  
408 subjective and objective knowledge levels regarding genetic non-discrimination regulations[35] and  
409 genetics generally [36]. However, although genetics HPs were more knowledgeable than non-genetics  
410 HPs, they appeared to overestimate their knowledge more than non-genetics HPs, indicating some  
411 mismatch between subjective and objective knowledge.

412

413 An area of historical misinformation is that of the impact of GD on health insurance. In our previous  
414 survey[18], 15% of HPs incorrectly stated that genetic information could be used for health insurance  
415 policies in Australia. In the current survey, a similar number (17%) of genetics HPs still answered this  
416 question incorrectly, as well as 50% of non-genetics HPs. The knowledge gap between genetic and  
417 non-genetic HPs overall was sizable, highlighting the need to train a wider range of HPs with the  
418 mainstreaming of genetic testing. Surprisingly, given the recent policy changes and need for  
419 dissemination and education around these changes, similar numbers of genetics HPs reported  
420 attending training in our previous survey (51%) as this survey (55%). Further, a smaller percentage of  
421 genetics HPs reported having read the CGE fact sheet (68%) than previously reported (85%)[18]. This



422 may explain the knowledge gaps despite clinician confidence (HPs who feel they have sufficient  
423 knowledge may be less likely to seek out additional resources).

424

425 A significant finding of the study is that many HPs (50%) believe the FSC moratorium applies to travel  
426 insurance, or are unsure of its application. As discussed, travel insurers are not restricted by the  
427 moratorium. Several HPs raised concerns about insurance implications for travel insurance in free-text  
428 comments regarding limitations of the moratorium and in the “final thoughts” section. This provides  
429 further support for the contention that broader government regulation and oversight of the use of  
430 genetic test results in insurance underwriting is required to adequately protect consumers.

431

432 Strengths of the current study include being the first of its kind to report HP views and experiences  
433 since the introduction of the FSC moratorium. Also, to our knowledge, our study provides the first  
434 example of a survey of HPs conducted both before and after the introduction of a major policy change  
435 regarding GD and life insurance. By asking similar questions as our previous (pre-moratorium) survey,  
436 we were able to undertake comparative analysis pre- and post-moratorium. Our survey reached a  
437 wide range of HPs, covering traditional genetics HPs as well as other clinicians who discuss genetic  
438 testing with patients.

439

440 Limitations of our study include the relatively small number of non-genetics HPs surveyed, which may  
441 limit the generalisability to this group. HPs were asked some questions about patient experiences,  
442 which is arguably second-hand information. Other studies, which will seek firsthand  
443 experiences/perceptions of patients and consumers, are being developed as part of the A-GLIMMER  
444 Project[37] to address this limitation. Given the rising prominence of the issue of life insurance  
445 discrimination in Australia, response bias is a potential limitation. We attempted to address this by  
446 making it an option for HPs to remain anonymous if they preferred. Further, views expressed by HPs  
447 who were happy to be contacted (~20% of HPs) will be explored further through qualitative interviews,

448 in a subsequent study. Our survey was conducted less than a year after the introduction of the FSC  
449 moratorium (9 months). Although this was intentional to ensure data collection and analysis could  
450 take place to inform the review of the moratorium, waiting longer could have resulted in different  
451 responses and experiences from HPs. As the survey was conducted online and in early 2020, it is not  
452 expected that COVID restrictions significantly affected participation.

453

#### 454 **Conclusion**

455 Many Australian genetic HPs know about the FSC moratorium and have knowledge of its specifics;  
456 however, some genetic HPs and many non-genetics HPs do not. Australian HPs report some  
457 improvement for consumers as a result of the moratorium's introduction, but concerns about GD in  
458 life insurance remain. HPs describe strong views about perceived limitations of the moratorium,  
459 including industry self-regulation and lack of government oversight, as well as the inadequacy of the  
460 current financial limits and the uncertainty around the moratorium's temporary nature. A majority of  
461 Australian HPs believe government oversight of the FSC moratorium is required, and that legislation  
462 regarding genetic testing and life insurance should also be considered in Australia. Our findings will  
463 assist with developing recommendations for the Australian government to consider future policy and  
464 regulatory changes in this area, and will be of interest to other jurisdictions internationally who are  
465 grappling with similar issues around the regulation of GD in life insurance.

466

467

468

469

#### 470 **Figure legends**

471 Figure 1: Awareness, knowledge, training

472 Figure 2: Patient impact and views on regulation

473 Figure 3: Summary of findings

474 **Declarations**

475

476 ***Funding (information that explains whether and by whom the research was supported)***

477 The project is supported by a grant from the Australian Government’s Medical Research Future Fund  
478 (MRFF), ref 76721. AML is funded by a National Health and Medical Research Council (NHMRC) Early  
479 Career Fellowship (ID 1158111). PL is supported by a National Heart Foundation Future Leader  
480 Fellowship (ID 102604).

481

482 ***Conflicts of interest/Competing interests (include appropriate disclosures)***

483 The authors declare no conflicts of interest or competing interests

484

485 ***Availability of data and material (data transparency)***

486 Numerous data are made available via supplementary materials. Additional data can be made  
487 available on reasonable request.

488

489 ***Code availability (software application or custom code)***

490 N/A

491

492 ***Authors' contributions (optional: please review the submission guidelines from the journal  
493 whether statements are mandatory)***

494

495

496 ***Ethics approval (include appropriate approvals or waivers)***

497 This project was granted approval by the Monash University Human Research Ethics Committee on 11  
498 March 2020, ID number 22576, and was performed in accordance with the ethical standards as laid  
499 down in the 1964 Declaration of Helsinki.

500

501 ***Consent to participate (include appropriate statements)***

502 The Explanatory Statement provided to participants includes the following statement: “Participation  
503 is completely voluntary and you are able to withdraw at any time. However, if you chose to remain  
504 anonymous in completing the survey, we will not be able to identify your data in order to exclude it  
505 from analysis.”

506

507 The first question of the online survey completed by participants (following the reading of the  
508 Explanatory Statement) was as follows:

509 “By continuing with this survey, you give your consent to being a participant in this research project

510

- Continue with survey
- I do not want to continue with this survey” (survey ended if this response was selected)

511

512

513 ***Consent for publication (include appropriate statements)***

514 The Explanatory Statement provided to participants includes the following statement: “The data  
515 collected will be de-identified so that the source of each response is not known, and the de-identified  
516 data will be analysed and submitted for publication in a peer-reviewed journal.”

517

518

## 519 References

- 520 1. Joly Y, Dalpé G, Dupras C, et al. Establishing the International Genetic Discrimination Observatory.  
521 Nature Genetics 2020;**52**(5):466-68 doi: 10.1038/s41588-020-0606-5[published Online First:  
522 Epub Date]].
- 523 2. Joly Y, Dupras C, Pinesz M, et al. Looking Beyond GINA: Policy Approaches to Address Genetic  
524 Discrimination. Annual Review of Genomics and Human Genetics 2020;**21**(1):491-507 doi:  
525 10.1146/annurev-genom-111119-011436[published Online First: Epub Date]].
- 526 3. Joly Y, Feze IN, Song L, et al. Comparative Approaches to Genetic Discrimination: Chasing  
527 Shadows? Trends in Genetics 2017
- 528 4. Tiller J, Otlowski M, Lacaze P. Should Australia Ban the Use of Genetic Test Results in Life  
529 Insurance? Frontiers in Public Health 2017;**5**(330) doi: 10.3389/fpubh.2017.00330[published  
530 Online First: Epub Date]].
- 531 5. Keogh LA, Niven H, Rutstein A, et al. Choosing not to undergo predictive genetic testing for  
532 hereditary colorectal cancer syndromes: expanding our understanding of decliners and  
533 declining. Journal of Behavioral Medicine 2017:1-12
- 534 6. Keogh LA, Otlowski M. Life insurance and genetic test results: a mutation carrier's fight to achieve  
535 full cover. Med J Aust 2013;**199**(5):363-66
- 536 7. Keogh LA, van Vliet CM, Studdert DM, et al. Is uptake of genetic testing for colorectal cancer  
537 influenced by knowledge of insurance implications? Medical Journal of Australia  
538 2009;**191**(5):255
- 539 8. Smit AK, Keogh LA, Newson AJ, et al. Exploring the Potential Emotional and Behavioural Impact of  
540 Providing Personalised Genomic Risk Information to the Public: A Focus Group Study. Public  
541 Health Genomics 2015;**18**(5):309-17 doi: 10.1159/000439246[published Online First: Epub  
542 Date]].
- 543 9. Green RC, Lautenbach D, McGuire AL. GINA, Genetic Discrimination, and Genomic Medicine. New  
544 England Journal of Medicine 2015;**372**(5):397-99 doi: 10.1056/NEJMp1404776[published  
545 Online First: Epub Date]].
- 546 10. Wauters A, Van Hoyweghen I. Global trends on fears and concerns of genetic discrimination: a  
547 systematic literature review. J Hum Genet 2016;**61**(4):275-82 doi:  
548 10.1038/jhg.2015.151[published Online First: Epub Date]].
- 549 11. Australian Law Reform Commission. Essentially Yours: The Protection of Human Genetic  
550 Information in Australia. Secondary Essentially Yours: The Protection of Human Genetic  
551 Information in Australia 2003. <http://www.alrc.gov.au/publications/report-96>.
- 552 12. Newson AJ, Tiller J, Keogh LA, et al. Genetics and Insurance in Australia: Concerns around a Self-  
553 Regulated Industry. Public Health Genomics 2017;**20**(4):247-56
- 554 13. Hayne K. Final Report - Royal Commission into Misconduct in the Banking, Superannuation and  
555 Financial Services Industry. Canberra, 2019.
- 556 14. Commonwealth of Australia. Parliamentary Joint Committee on Corporations and Financial  
557 services - life insurance industry. Secondary Parliamentary Joint Committee on Corporations  
558 and Financial services - life insurance industry 2018.  
559 [https://www.aph.gov.au/Parliamentary\\_Business/Committees/Joint/Corporations\\_and\\_Financial\\_Services/LifeInsurance/Report](https://www.aph.gov.au/Parliamentary_Business/Committees/Joint/Corporations_and_Financial_Services/LifeInsurance/Report).
- 560
- 561 15. Financial Services Council. FSC ANNOUNCES MORATORIUM ON GENETIC TESTS FOR LIFE  
562 INSURANCE TO START IN JULY 2019, 2018.
- 563 16. Financial Services Council. FSC Standard No. 11: Moratorium on Genetic Tests in Life Insurance,  
564 2019.
- 565 17. Financial Services Council. Life Insurance Code of Practice, 2019.
- 566 18. Tiller J, Keogh L, Wake S, et al. Genetics, insurance and professional practice: Survey of the  
567 Australasian clinical genetics workforce. Frontiers in Public Health 2018;**6**:333
- 568 19. Human Genetics Society of Australasia. Process of Genetic Counselling. Sydney, 2008.

- 569 20. Otlowski M, Tiller J, Barlow-Stewart K, et al. Genetic testing and insurance in Australia. Australian  
570 Journal for General Practitioners 2019;**48**:96-99
- 571 21. White S, Jacobs C, Phillips J. Mainstreaming genetics and genomics: a systematic review of the  
572 barriers and facilitators for nurses and physicians in secondary and tertiary care. Genetics in  
573 Medicine 2020;**22**(7):1149-55 doi: 10.1038/s41436-020-0785-6[published Online First: Epub  
574 Date]].
- 575 22. Tiller J, Winship I, Otlowski MF, et al. Monitoring the genetic testing and life insurance  
576 moratorium in Australia: a national research project. Medical Journal of Australia 2021 doi:  
577 <https://doi.org/10.5694/mja2.50922>[published Online First: Epub Date]].
- 578 23. Tiller J, McInerney-Leo A, Belcher A, et al. Study protocol: the Australian genetics and life  
579 insurance moratorium-monitoring the effectiveness and response (A-GLIMMER) project.  
580 BMC Med Ethics 2021;**22**(1):63 doi: 10.1186/s12910-021-00634-2[published Online First:  
581 Epub Date]].
- 582 24. Harris PA, Taylor R, Thielke R, et al. A metadata-driven methodology and workflow process for  
583 providing translational research informatics support. J Biomed Inform 2009;**42**(2):377-81
- 584 25. StataCorp. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP, 2015.
- 585 26. Centre for Genetics Education. Fact Sheet 20 - Life insurance products and genetic testing in  
586 Australia Sydney, 2019.
- 587 27. Financial Services Council. Genetic tests and applying for life insurance – Key Facts, 2019.
- 588 28. Prince AER. Comparative perspectives: regulating insurer use of genetic information. European  
589 Journal of Human Genetics 2019;**27**(3):340-48 doi: 10.1038/s41431-018-0293-1[published  
590 Online First: Epub Date]].
- 591 29. Otlowski M, Taylor S, Bombard Y. Genetic discrimination: international perspectives. Annual  
592 review of genomics and human genetics 2012;**13**:433-54
- 593 30. Rothstein MA, Brothers KB. Banning Genetic Discrimination in Life Insurance — Time to Follow  
594 Florida’s Lead. New England Journal of Medicine 2020;**383**(22):2099-101 doi:  
595 10.1056/NEJMp2024123[published Online First: Epub Date]].
- 596 31. HM Government and Association of British Insurers. Code on Genetic Testing and Insurance.  
597 Secondary Code on Genetic Testing and Insurance 2018.  
598 [https://www.abi.org.uk/globalassets/files/publications/public/genetics/code-on-genetic-](https://www.abi.org.uk/globalassets/files/publications/public/genetics/code-on-genetic-testing-and-insurance-final.pdf)  
599 [testing-and-insurance-final.pdf](https://www.abi.org.uk/globalassets/files/publications/public/genetics/code-on-genetic-testing-and-insurance-final.pdf).
- 600 32. Shields AE, Burke W, Levy DE. Differential use of available genetic tests among primary care  
601 physicians in the United States: results of a national survey. Genetics in medicine  
602 2008;**10**(6):404-14
- 603 33. Lowstuter KJ, Sand S, Blazer KR, et al. Influence of genetic discrimination perceptions and  
604 knowledge on cancer genetics referral practice among clinicians. Genetics in Medicine  
605 2008;**10**(9):691-98
- 606 34. Petit C, Croisetière A, Chen F, et al. Are pharmacists from the province of Quebec ready to  
607 integrate pharmacogenetics into their practice. Pharmacogenomics 2020;**21**(4):247-56 doi:  
608 10.2217/pgs-2019-0144[published Online First: Epub Date]].
- 609 35. Laedtke AL, O’Neill SM, Rubinstein WS, et al. Family Physicians’ Awareness and Knowledge of the  
610 Genetic Information Non-Discrimination Act (GINA). Journal of Genetic Counseling  
611 2012;**21**(2):345-52 doi: 10.1007/s10897-011-9405-6[published Online First: Epub Date]].
- 612 36. Douma KF, Smets EM, Allain DC. Non-genetic health professionals’ attitude towards, knowledge  
613 of and skills in discussing and ordering genetic testing for hereditary cancer. Familial cancer  
614 2016;**15**(2):341-50
- 615 37. Tiller J, McInerney-Leo A, Belcher A, et al. Study protocol: the Australian genetics and life  
616 insurance moratorium - monitoring the effectiveness and response (A-GLIMMER) project.  
617 BMC Medical Ethics 2021;(in press) doi: [https://doi.org/10.1186/s12910-021-00634-](https://doi.org/10.1186/s12910-021-00634-2)  
618 [2](https://doi.org/10.1186/s12910-021-00634-2)[published Online First: Epub Date]].

**Table 1: Characteristics of the surveyed population (n=166)**

<i>Demographic</i>	<i>Category</i>	<i>Number (%)</i>
<b>Sex</b>	Female	124 (75%)
	Male	40 (24%)
	Other	2 (1%)
<b>Location</b>	ACT	4 (2%)
	NSW	41 (25%)
	NT	1 (1%)
	QLD	17 (10%)
	SA	6 (4%)
	TAS	4 (2%)
	VIC	65 (40%)
	WA	28 (17%)
<b>Profession</b>	Associate genetic counsellor	59 (36%)
	Certified genetic counsellor	38 (23%)
	Clinical Geneticist	14 (8%)
	Genetics Fellow	10 (6%)
	Other	45 (27%)
<b>Years of Experience</b>	0-5 years	60 (36%)
	6-10 years	33 (20%)
	11-15 years	21 (13%)
	15-20 years	21 (13%)
	> 20 years	31 (18%)
<b>Average number of appointments with patients considering testing (per fortnight)</b>	0-5	68 (40%)
	6-10	70 (41%)
	11-20	24 (14%)
	>20	8 (5%)

**Table 2: Awareness, knowledge, training**

Question		Responses	Genetics HPs (%)	Non-genetics HPs (%)	TOTAL (%)
Are you aware that there was a change in policy on 1 July 2019 and a moratorium was introduced on the use of genetic testing in life insurance underwriting? (n=166)	No		3/121 (2)	21/45 (47)	24/166 (14)
	Yes		118/121 (98)	24/45 (53)	142/166 (86)
[if yes] How did you become aware? (n=142) * more than one option could be selected	My health service		64/118 (54)	7/24 (29)	71/142 (50)
	A news source		12/118 (10)	10/24 (42)	22/142 (15)
	HGSA		96/118 (81)	4/24 (17)	100/142 (70)
	Insurance industry		4/118 (3)	0/24 (0)	4/142 (3)
Has your health service provided, or have you attended, any training or information sessions regarding the moratorium and insurance implications of genetic testing? (n=166)	Yes, formal training		7/121 (6)	0/45 (0)	7/166 (4)
	Yes, information sessions		60/121 (49)	3/45 (7)	63/166 (38)
	No		54/121 (45)	42/45 (93)	96/166 (58)
How well do you feel you now understand insurance implications for individuals undergoing genetic testing? (n=166)	Extremely well		12/121 (10)	0/45 (0)	12/166 (7)
	Reasonably well		89/121 (74)	17/45 (38)	106/166 (64)
	Not particularly well		17/121 (14)	17/45 (38)	34/166 (20)
	Not well at all		3/121 (2)	11/45 (24)	14/166 (8)
Do you feel you have sufficient knowledge about the current insurance implications of genetic testing to properly advise patients? (n=166)	Yes		98/121 (81)	16/45 (36)	114/166 (69)
	No		23/121 (19)	29/45 (64)	52/166 (31)
Are you aware of, and have you read, these fact sheets? (n=158)	The updated HGSA position statement on Genetic Testing and Life Insurance (updated after announcement of moratorium)	I am aware of it and I have read it	49/117 (42)	9/42 (21)	58/158 (37)
		I am aware of it, but have not yet read it	42/117 (36)	13/42 (31)	55/158 (35)
		I am not aware of it	26/117 (22)	20/42 (48)	46/158 (29)
	Fact Sheet 20 published by the Centre for Genetics Education (updated mid-2019)	I am aware of it and I have read it	79/117 (68)	7/42 (17)	86/158 (54)
		I am aware of it, but have not yet read it	17/117 (15)	6/42 (14)	23/158 (15)
		I am not aware of it	21/117 (18)	28/42 (67)	49/158 (31)
	The Financial Services Council (FSC) Standard No 11 on Genetic testing (updated to include the moratorium in mid-2019)	I am aware of it and I have read it	29/117 (25)	6/42 (14)	35/158 (22)
		I am aware of it, but have not yet read it	42/117 (36)	7/42 (17)	49/158 (31)
		I am not aware of it	46/117 (39)	28/42 (67)	74/158 (47)
	The FSC fact sheet on the life insurance moratorium	I am aware of it and I have read it	51/117 (44)	11/42 (26)	62/158 (39)
		I am aware of it, but have not yet read it	18/117 (15)	2/42 (5)	20/158 (13)
		I am not aware of it	48/117 (41)	28/42 (67)	76/158 (48)
Number of knowledge questions answered correctly (n=146) (for question-specific data see Supplementary Table S2)  Mean score (Genetics HPs): 4.5 Mean score (Non-genetics HPs): 3.1	0	"Poor knowledge"	1/110 (1)	4/36 (11)	5/146 (3)
	1		0/110 (0)	5/36 (14)	5/146 (3)
	2		1/110 (1)	4/36 (11)	5/146 (3)
	3	"Average knowledge"	14/110 (13)	7/36 (19)	21/146 (14)
	4		34/110 (31)	5/36 (14)	39/146 (27)
	5	"Good knowledge"	41/110 (37)	7/36 (19)	48/146 (33)
	6		19/110 (17)	4/36 (11)	23/146 (16)



**Table 3: Impact on practice and clients**

Question		Responses	Genetics HPs (%)	Non-genetics HPs (%)	TOTAL (%)
Is there a statement about insurance implications.. (n=150)	On your consent form, where you have a specific form for predictive genetic testing in adults (n=51)	Yes	34/38 (89)	9/13 (69)	43/51 (84)
		No	4/38 (11)	4/13 (31)	8/51 (16)
	On your consent form, where you have a standard form for all genetic testing (n=99)	Yes	60/75 (80)	6/24 (25)	66/99 (67)
		No	15/75 (20)	18/24 (75)	33/99 (33)
Has your consent form been updated following the introduction of the moratorium on 1 July 2019? (n=151)		Yes	24/113 (21)	4/38 (11)	28/151 (18)
		No	67/113 (59)	8/38 (21)	75/154 (50)
		I don't know	22/113 (19)	26/38 (68)	48/154 (32)
How often do you estimate patients delayed predictive testing (n=154)	Due to life, income or trauma/critical illness insurance concerns, before the moratorium was introduced?	Never	1/121 (1)	5/45 (11)	6/154 (4)
		Rarely	41/121 (34)	11/45 (24)	52/154 (34)
		Sometimes	68/121 (56)	19/45 (42)	87/154 (56)
		Often	5/121 (4)	5/45 (11)	10/154 (6)
	Due to life, income or trauma/critical illness insurance concerns, after the moratorium was introduced?	Never	12/121 (10)	5/45 (11)	17/154 (11)
		Rarely	62/121 (51)	15/45 (33)	77/154 (50)
		Sometimes	40/121 (33)	18/45 (40)	58/154 (38)
		Often	0/121 (0)	2/45 (4)	2/154 (1)
	Due to travel insurance concerns?	Never	47 /121 (39)	14/45 (31)	61/154 (40)
		Rarely	60/121 (49)	16/45 (36)	76/154 (49)
		Sometimes	7/121 (6)	5/45 (11)	12/154 (8)
		Often	0/121 (0)	5/45 (11)	5/154 (3)
How often do you estimate patients refused predictive testing (n=154)	Due to life, income or trauma/critical illness insurance concerns, before the moratorium was introduced?	Never	11/121 (9)	7(16)	17/154 (11)
		Rarely	76/121 (63)	12/45 (27)	77/154 (50)
		Sometimes	26/121 (21)	19/45 (42)	58/154 (38)
		Often	2 /121 (2)	2/45 (4)	2/154 (1)
	Due to life, income or trauma/critical illness insurance concerns, after the moratorium was introduced?	Never	28/121 (23)	6/45 (13)	34/154 (22)
		Rarely	75/121 (62)	18/45 (40)	93/154 (60)
		Sometimes	11/121 (9)	15/45 (33)	26/154 (17)
		Often	0/121 (0)	1/45 (2)	1/154 (1)
	Due to travel insurance concerns?	Never	56/121 (46)	16/45 (36)	72/154 (47)
		Rarely	50/121 (41)	14/45 (31)	64/154 (42)
		Sometimes	8/121 (7)	8/45 (18)	16/154 (10)
		Often	0/121 (0)	2/45 (4)	2/154 (1)
Since the introduction of the moratorium, have patient/s told you about having had an adverse insurance outcome on the basis of genetic test results? (for example, having difficulty obtaining a policy, having an increased premium, or having a policy application denied)? (n=153)		Yes	3/114 (3)	2/39 (5)	5/153 (3)
		No	111/114 (97)	37/39 (95)	148/153 (97)

**Table 4: Views on FSC moratorium and regulation**

Question		Responses	Genetics HPs (%)	Non-genetics HPs (%)	TOTAL (%)
Please indicate the degree to which you agree with the following statements	The moratorium is easy to understand (n=145)	Strongly agree	0/113 (0)	0/35 (0)	0/145 (0)
		Agree	89/110 (81)	27/35 (77)	116/145 (80)
		Disagree	18/110 (16)	6/35 (17)	24/145 (17)
		Strongly disagree	3/110 (3)	2/35 (6)	5/145 (3)
	The moratorium is easy to explain to patients (n=144)	Strongly agree	1/110 (1)	0/35 (0)	1/144 (1)
		Agree	80/109 (73)	28/35 (80)	108/144 (75)
		Disagree	25/109 (23)	5/35 (14)	30/144 (21)
		Strongly disagree	3/109 (3)	2/35 (6)	5/144 (3)
	Patients are less confused than they used to be about insurance implications of genetic testing (n=144)	Strongly agree	5/109 (5)	0/35 (0)	5/144 (3)
		Agree	51/109 (47)	17/35 (49)	68/144 (47)
		Disagree	49/109 (45)	17/35 (49)	66/144 (46)
		Strongly disagree	4/109 (4)	1/35 (3)	5/144 (3)
	Patients are more willing to have predictive genetic testing than they were before the moratorium was introduced (n=144)	Strongly agree	6/109 (5)	0/35 (0)	6/144 (4)
		Agree	60/109 (55)	19/35 (54)	79/144 (55)
		Disagree	39/109 (36)	15/35 (43)	54/144 (38)
		Strongly disagree	4/109 (4)	1/35 (3)	5/144 (3)
	The moratorium has resolved some concerns I had about insurance discrimination (n=144)	Strongly agree	5/109 (5)	2/35 (6)	7/144 (5)
		Agree	82/109 (75)	21/35 (60)	103/144 (72)
		Disagree	21/109 (19)	10/35 (29)	31/144 (22)
		Strongly disagree	1/109 (1)	2/35 (6)	3/144 (2)
	After the introduction of the moratorium, I still have concerns about insurance discrimination (n=144)	Strongly agree	22/109 (20)	4/35 (11)	26/144 (18)
		Agree	76/109 (70)	25/35 (71)	101/144 (70)
		Disagree	9/109 (8)	4/35 (11)	13/144 (9)
		Strongly disagree	2/109 (2)	2/35 (6)	4/144 (3)
	Consumers are better protected post-moratorium than they were before the moratorium was introduced (n=144)	Strongly agree	18/109 (16)	2/35 (6)	20/144 (14)
		Agree	84/109 (77)	30/35 (86)	114/144 (79)
		Disagree	7/109 (6)	3/35 (9)	10/144 (7)
		Strongly disagree	0/109 (0)	0/35 (0)	0/144 (0)
Based on your professional experience, how do you feel about the moratorium as a solution to genetic discrimination in life insurance? (n=149)	Very satisfied	6/113 (5)	0/36 (0)	6/149 (4)	
	Somewhat satisfied	52/113 (46)	18/36 (13)	70/149 (47)	
	Somewhat dissatisfied	49/113 (46)	12/36 (9)	61/149 (41)	
	Very dissatisfied	6/113 (5)	6/36 (4)	12/149 (8)	
In your opinion, how should insurers' compliance with the moratorium on using genetic test results in life insurance be regulated? (n=149) * more than one option could be selected	Self-regulation by the life insurance industry (FSC)	16/113 (14)	4/36 (11)	20/149 (13)	
	Regulation through legally enforceable rules	102/113 (90)	29/36 (81)	131/149 (88)	
	Other	2/113 (2)	3/36 (8)	5/149 (3)	
In the UK, there is a moratorium that involves a formal agreement between the UK government and the Life Insurance Industry. Do you think a formal agreement between the Australian government and industry (Financial Services Council) is required on this issue in Australia? (n=149)	Yes	108/113 (96)	33/36 (92)	141/149 (95)	
	No	5/113 (4)	3/36 (8)	8/149 (5)	
Do you think the Australian government should introduce legislation to regulate the use of genetic test results in life insurance? (n=149)	Yes	105/113 (93)	34/36 (94)	139/149 (93)	
	No	8/113 (7)	2/36 (6)	10/149 (7)	

**Table 5a: Perceived *benefits* of the current genetics and life insurance moratorium in Australia**

Benefit (n=62)	n (%) <sup>*</sup>	Example quote(s)	Participant # (qualification, yrs' experience)
Increased reassurance/ patients more willing to have genetic testing	21 (34%)	<i>Easing concerns for patients who may now have some level of cover if at high genetic risk. By doing this it lessens the potential negative implications of predictive testing and therefore decision making can be focused more on the health implications.</i>	P21 (GC, 10-15 y)
		<i>It's a step in the right direction and patients with minor concerns/reluctance feel reassured</i>	P108 (GC, 0-5 y)
Some protection provided	19 (31%)	<i>Provides at least some level of insurance that may not have been available at all previously</i>	P42 (GC, 10-15 y)
		<i>People can access some level of insurance without the threat of discrimination based on their genetic test result</i>	P199 (GC, 0-5 y)
Increased clarity	9 (15%)	<i>From my practice point of view, having some clear guidelines to present to clients/patients, rather than it all being very dependent on the individual insurer.</i>	P129 (GC, 0-5 y)
Family implications	6 (10%)	<i>Most people are concerned about what the insurance implications are for their children. It is helpful to be able to let them know that their children only need to disclose their parent's health conditions not their genetic test result.</i>	P136 (GC, 0-5 y)
Heightened awareness/ recognition of issue	5 (8%)	<i>More awareness of the issue, hopefully future stronger protections for patients depending on how effective the moratorium can be shown to be currently.</i>	P130 (GC, 6-10 y)
"Step in the right direction"	3 (5%)	<i>It is a step in the right direction but insurance concerns are still present for many patients and providers</i>	P108 (GC, 0-5 y)
Provides time	2 (3%)	<i>Gives time to find better solution</i>	P98 (GC, 15-20 y)
* participants may have listed multiple benefits in their free-text response GC=Genetic Counsellor; CG = Clinical Geneticist			

**Table 5b: Perceived limitations of the current genetics and life insurance moratorium in Australia**

Limitation (n=64)	n (%)*	Example quote(s)	Participant # (qualification, yrs' experience)
Insurance companies' compliance/self-regulation	29 (45%)	<i>It would be better if there was NO discrimination at all, that was made law and insurance companies held accountable (not self-regulated).</i>	P129 (GC, 0-5 y)
		<i>It is self-regulated and not legally enforceable, so only as good as the trust in the industry generally</i>	P89 (GC, 0-5 y)
Financial limits	28 (44%)	<i>The limit on cover is relatively low. Despite industry assurance that most policies fall below this threshold a significant number of patients see this as limiting</i>	P229 (CG 15-20 y)
		<i>The amounts are too low and won't give enough reassurance to some.</i>	P135 (CG >20 y)
Temporary nature of moratorium	17 (27%)	<i>The uncertainty about how long it will be in place - we need this to be PERMANENT to enable patients not to fear having genetic testing because of insurance concerns as genetic testing can really influence their physical AND psychological health</i>	P149 (GC 15-20 y)
		<i>The uncertainty of how this will apply in the future if someone wants to take out a policy in a few years and the moratorium no longer applies.</i>	P173 (GC, 0-5 y)
Restricted application	8 (13%)	<i>Not all insurers are FSC Members. It doesn't apply to all life insurance policies, only those under certain amounts. Only applies to policies from 1 July 2019, ie not pre-existing too.</i>	P42 (GC, 11-15 y)
Travel insurance not covered	3 (5%)	<i>Travel insurance is a major exclusion. Many patients are concerned about implications for travel insurance especially when their work or family takes them to high cost medical care in countries such as USA.</i>	P195 (GC, 15-20 y)
Lack of dissemination	2 (3%)	<i>Many financial advisors and workers in the industry seem unaware of the moratorium.</i>	P207 (CG, >20 y)
* participants may have listed multiple limitations in their free-text response GC=Genetic Counsellor; CG = Clinical Geneticist			




Figure 1: Awareness, knowledge, training




Figure 2: Patient impact and views on regulation




Figure 3: Key findings